Navigation Links
Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
Date:7/26/2012

ROCKVILLE, Md., July 26, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it received a notice of issuance for patent number 12/710,097 titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including amytrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem is currently conducting a Phase I safety trial of its human spinal cord stem cells in the treatment of ALS.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"This is a major addition to our patent estate," said Neuralstem Chairman & Chief Scientific Officer, Karl Johe, PhD. "This patent includes claims covering processes for dissociating our neural stem cells from central nervous system tissue; culturing the cells; expanding the cells in vitro and transplanting the neural stem cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions including, amyotrophic lateral sclerosis (ALS)."

"We are pleased to have this new patent issued, which will expire in Q1 2030," said Neuralstem President & CEO, Richard Garr. "We have currently transplanted 17 patients in our ALS trial and we have been encouraged by the results so far.  We are focused on this program as our first potential transplantation product.  We believe that having this specific patent coverage as well as this patent life into 2030 is reflective of the value we are creating in our cell therapy programs."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively in
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. UCSB professor receives award for graphene electronics research
8. Watsons Generic Yaz(R) Receives FDA Approval
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
11. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced that a supplemental New Drug Application (sNDA) ... (FDA) for the expanded use of BYETTA® (exenatide) injection as ... and/or a thiazolidinedione (TZD) in conjunction with diet and exercise ...
... Santiago de Compostela (USC) have analysed levels of radon, a ... results show that 34% of these schools exceed the limit ... of radon is associated with lung cancer. "Out of ... radon levels in excess of 400 Bequerels/m3 in some of ...
... Screening Services (ESS), announced today that they have ... Professional Background Screeners (NAPBS®) accreditation program and will ... (BSCC) Accredited. "We are so pleased ... that we can instill confidence in our existing ...
Cached Biology Technology:Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 2Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 3Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 4Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 5Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 6Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 734 percent of Galician secondary schools exceed maximum recommended radon levels 2ESS Achieves Accreditation From Background Screening Credentialing Council 2
(Date:10/19/2014)... household electricity access in India over the last ... total carbon emissions growth during that time, according ... Nature Climate Change ., "Energy access is ... aspects of life, including education, communication, and health," ... study. , While increased energy access is widely ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... Researchers from Cleveland Clinic,s Wellness Institute and Harvard University ... sodas is associated with a higher risk of stroke. ... with a lower risk. The study recently ... is the first to examine soda,s effect ...
... surrounding the outside of arteries in humansparticularly the left ... or atherosclerosis, which is the leading cause of death ... the American Heart Association,s Arteriosclerosis, Thrombosis and Vascular Biology ... may help in identifying the molecular culprit, with the ...
... Scientists have identified a link between different strains of ... develop vaccines or drugs against life-threatening cases of the ... is common to many potentially fatal forms of the ... were effective against these severe malaria strains. The ...
Cached Biology News:Study finds soda consumption increases overall stroke risk 2Fat outside of arteries may influence onset of coronary artery disease 2Scientists find Achilles' heel in life-threatening malaria parasites 2
...
... TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) offer ... vitro translations: a single-tube, coupled transcription/translation ... simplify the process and reduce the ... translation results. Standard rabbit reticulocyte lysate ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
Biology Products: